AKBA: Akebia Therapeutics 2020-05-05 06:59:00 Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
followed by a 3 down to fib 76.4. Looks good for a wave 3 action.
Continuum of momentum with the news , expecting uptrend in directional and price appreciation for a whole next week . Target 6% here
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph...
Entry level $4.41 = target price $5.14 Average analysts price target $14.86 | Buy Company profile Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and...
risky knife catch, you must use a stop loss on this trade
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on the development and commercialization of therapeutics for patients with kidney disease. Today's activity in the option market signals that a massive move is imminent, we are following that trade.
Looking for a good strong next green candle above the previous. on strong volume and float! it past previous highs for many days. a great call.
I will be entering this stock. Same rules apply, have SL under the channel. Risk reward.
AKBA had a good upward run forming a fallen angel formation, and now after some consolidation it seems getting ready for a second run.It has a fair amount of insider buying going on. We think it has very good upside potential if it can break around $16.60. To play this we would consider October $15 calls, which are $1.45/$1.75 * Trade Criteria * Date First...
Next stop on AKBA $17.20. Even though the RSI is in the overbought condition, stocks tend to make their best moves in these conditions. Breaks the high of $15.88 and it is a great SWING. We are late to the party on this one. Happy Trading!
With Monthly RS making ATH just a matter of time before the stock moves to ATH at 28.
$AKBA in a wild coil on daily. Positive divergences on RSI indicate a move north. OI is also strong for 10 calls. Looking for a move up.
I am not use to with Fib resistance arcs but it looks very realistic. according to this criterion the up trend fits well. Caution remains due to earning on monday 14th.